Compare Nutanix Inc (NTNX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Revvity Inc — how do they compare? Nutanix Inc trades at $74.59 (market cap $19.78B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Nutanix Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Revvity Inc for 12 Days on average.
| NTNX | RVTY | |
|---|---|---|
Market Cap | $19.78B | $16.98B |
Volume | 1,717,619 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $73.42 | $157.36 |
52-Week Low | $34.41 | $82.26 |
Typical Hold Time | 17 Days | 12 Days |
Enterprise Value | $18.94B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $73.98, up 0.76% today, with a bullish technical signal from moving averages and strong recent earnings beats. The company reported robust profitability with a net income margin of 52.81% for 2026 and is recognized as a leader in multiple Gartner Magic Quadrant reports, highlighting its competitive strength in hybrid cloud infrastructure.
The outlook is positive with analyst consensus favoring a buy rating and a $76.11 price target, though risks include high valuation multiples like a 46.22 EV/EBITDA and negative ROE. Revenue growth and external storage expansion present opportunities, but investors should monitor execution against guidance and market volatility.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
